NCT01867047

ACE-Inhibitor Effects on Total Hip and Knee Arthroplasty Patients

Effects of Angiotensin Converting Enzyme Inhibitors on Total Hip and Knee Arthroplasty Patients

• Status: Terminated
• Phase: N/A
• Study type: Interventional
• Enrollment: 59 (actual)
• Sponsor: Duke University · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to determine the effects of Angiotension Converting Enzyme Inhibitors (ACE-I) during surgery and in the immediate postoperative period for patients undergoing elective total hip or knee arthroplasty.

Conditions

• Adverse Effects of Angiotensin-converting-enzyme Inhibitors
• Hypotension

Interventions

Type	Name	Description
DRUG	ACE-I Cessation group	Subjects stop ACE-I 48 hours prior to surgery. Examples of possible ACE-I drugs include: benazepril (Lotensin), captopril (Capoten), enalapril (Vasotec, Epaned), fosinopril (Monopril), lisinopril (Prinivil, Zestril), moexipril (Univasc), perindopril (Aceon), quinapril (Accupril), ramipril (Altace), trandolapril (Mavik)
DRUG	ACE-I Continuation group	Subjects take ACE-I through day of surgery. Examples of possible ACE-I drugs include: benazepril (Lotensin), captopril (Capoten), enalapril (Vasotec, Epaned), fosinopril (Monopril), lisinopril (Prinivil, Zestril), moexipril (Univasc), perindopril (Aceon), quinapril (Accupril), ramipril (Altace), trandolapril (Mavik)

Timeline

• Start date: 2013-06-01
• Primary completion: 2016-06-24
• Completion: 2016-06-24
• First posted: 2013-06-03
• Last updated: 2017-09-28
• Results posted: 2017-09-28

Locations

1 site across 1 country: United States